Additionally, a string of assays both in vivo and in vitro were performed to verify the role of the LINC00663/EBF1/NR2F1 axis in BC progression, and results showed that silencing LINC00663 inhibited inflammation and angiogenesis in BC partially by decreasing NR2F1 expression via binding EBF1. Here, EBF1 is linked to breast cancer.